Smarter Decisions,
Better Care

UpToDate synthesizes the most recent medical information into evidence-based practical recommendations clinicians trust to make the right point-of-care decisions.

  • Rigorous editorial process: Evidence-based treatment recommendations
  • World-Renowned physician authors: over 5,100 physician authors and editors around the globe
  • Innovative technology: integrates into the workflow; access from EMRs

Choose from the list below to learn more about subscriptions for a:


Subscribers log in here


Pathogenesis of and risk factors for pelvic inflammatory disease

INTRODUCTION

Pelvic inflammatory disease (PID) refers to acute infection of the upper genital tract structures in women, involving any or all of the uterus, oviducts, and ovaries; this is often accompanied by involvement of the neighboring pelvic organs. By definition, PID is a community-acquired infection initiated by a sexually transmitted agent, distinguishing it from pelvic infections caused by medical procedures, pregnancy, and other primary abdominal processes.

Pelvic inflammatory disease in the United States annually accounts for about 2.5 million outpatient visits, 200,000 hospitalizations, and 100,000 surgical procedures [1]. It is the most frequent gynecologic cause for emergency department visits (350,000/year) and incurs an annual total expense of almost $2 billion [1,2]. However, costs of PID in the US have decreased in the last decade [3].

The pathogenesis of and risk factors for PID will be reviewed here. The clinical features, diagnosis, treatment, and sequelae of this disorder are discussed separately. (See "Clinical features and diagnosis of pelvic inflammatory disease" and "Treatment of pelvic inflammatory disease".)

PATHOGENESIS

The vaginal flora of most normal, healthy women includes a variety of potentially pathogenic bacteria [4]. Among these are species of streptococci, staphylococci, Enterobacteriaceae (most commonly Klebsiella spp, Escherichia coli, and Proteus spp), and a variety of anaerobes. Compared with the dominant hydrogen peroxide-producing Lactobacillus acidophilus, these organisms are present in low numbers, and ebb and flow under the influence of hormonal changes (pregnancy, degree of estrogenization), contraceptive method, sexual activity, and other as yet unknown forces.

Complete disruption of the vaginal ecosystem can occur, in which anaerobic bacteria assume predominance over the desirable strains of lactobacilli. This condition is known as bacterial vaginosis, which is not associated with an inflammatory response [5]. Bacterial vaginosis affects 15 to 30 percent of American women, one-half of whom are asymptomatic [6]. Its significance is not clearly understood but when found in pregnancy, bacterial vaginosis was an independent risk factor for preterm delivery of a low birthweight infant in a study of 10,397 women of whom 16 percent had the diagnosis [7]. An intermediate situation in which H202-producing lactobacilli and anaerobes coexist in roughly equal numbers is called a transitional flora.

                  

Subscribers log in here

To continue reading this article, you must log in with your personal, hospital, or group practice subscription. For more information or to purchase a personal subscription, click below on the option that best describes you:
Literature review current through: Nov 2014. | This topic last updated: Aug 17, 2012.
The content on the UpToDate website is not intended nor recommended as a substitute for medical advice, diagnosis, or treatment. Always seek the advice of your own physician or other qualified health care professional regarding any medical questions or conditions. The use of this website is governed by the UpToDate Terms of Use ©2014 UpToDate, Inc.
References
Top
  1. Washington AE, Katz P. Cost of and payment source for pelvic inflammatory disease. Trends and projections, 1983 through 2000. JAMA 1991; 266:2565.
  2. Curtis KM, Hillis SD, Kieke BA Jr, et al. Visits to emergency departments for gynecologic disorders in the United States, 1992-1994. Obstet Gynecol 1998; 91:1007.
  3. Rein DB, Kassler WJ, Irwin KL, Rabiee L. Direct medical cost of pelvic inflammatory disease and its sequelae: decreasing, but still substantial. Obstet Gynecol 2000; 95:397.
  4. Galask RP, Larsen B, Ohm MJ. Vaginal flora and its role in disease entities. Clin Obstet Gynecol 1976; 19:61.
  5. Platz-Christensen JJ, Mattsby-Baltzer I, Thomsen P, Wiqvist N. Endotoxin and interleukin-1 alpha in the cervical mucus and vaginal fluid of pregnant women with bacterial vaginosis. Am J Obstet Gynecol 1993; 169:1161.
  6. Fleury FJ. Adult vaginitis. Clin Obstet Gynecol 1981; 24:407.
  7. Hillier SL, Nugent RP, Eschenbach DA, et al. Association between bacterial vaginosis and preterm delivery of a low-birth-weight infant. The Vaginal Infections and Prematurity Study Group. N Engl J Med 1995; 333:1737.
  8. Paavonen J, Aine R, Teisala K, et al. Comparison of endometrial biopsy and peritoneal fluid cytologic testing with laparoscopy in the diagnosis of acute pelvic inflammatory disease. Am J Obstet Gynecol 1985; 151:645.
  9. Eschenbach DA. Acute pelvic inflammatory disease: etiology, risk factors and pathogenesis. Clin Obstet Gynecol 1976; 19:147.
  10. U.S. Public Health Service. V.D. fact sheet, 1976. Publication No. (CDC) 77-8195, USPHS; 1976.
  11. Morse SA, Trees DL. Prevalence and treatment of multi-drug resistant Neisseria gonorrhoeae. Infect Med 1995; 12:609.
  12. Centers for Disease Control and Prevention (CDC). Update to CDC's sexually transmitted diseases treatment guidelines, 2006: fluoroquinolones no longer recommended for treatment of gonococcal infections. MMWR Morb Mortal Wkly Rep 2007; 56:332.
  13. Rendtroff RC, Curran JW, Chandler RW, et al. Economic consequences of gonorrhea in women: experience from an Urban hospital. J Am Vener Dis Assoc 1974; 1:40.
  14. Forslin L, Falk V, Danielsson D. Changes in the incidence of acute gonococcal and nongonococcal salpingitis. A five-year study from an urban area of central Sweden. Br J Vener Dis 1978; 54:247.
  15. Eschenbach DA, Buchanan TM, Pollock HM, et al. Polymicrobial etiology of acute pelvic inflammatory disease. N Engl J Med 1975; 293:166.
  16. Treharne JD, Ripa KT, Mårdh PA, et al. Antibodies to Chlamydia trachomatis in acute salpingitis. Br J Vener Dis 1979; 55:26.
  17. Recommendations of the International Task Force for Disease Eradication. MMWR Recomm Rep 1993; 42:1.
  18. Centers for Disease Control and Prevention (CDC). Ten leading nationally notifiable infectious diseases--United States, 1995. MMWR Morb Mortal Wkly Rep 1996; 45:883.
  19. Bowie WR, Jones H. Acute pelvic inflammatory disease in outpatients: association with Chlamydia trachomatis and Neisseria gonorrhoeae. Ann Intern Med 1981; 95:685.
  20. Arya OP, Mallinson H, Goddard AD. Epidemiological and clinical correlates of chlamydial infection of the cervix. Br J Vener Dis 1981; 57:118.
  21. Mosure DJ, Berman S, Fine D, et al. Genital Chlamydia infections in sexually active female adolescents: do we really need to screen everyone? J Adolesc Health 1997; 20:6.
  22. Scholes D, Stergachis A, Heidrich FE, et al. Prevention of pelvic inflammatory disease by screening for cervical chlamydial infection. N Engl J Med 1996; 334:1362.
  23. United States Preventive Service Task Force. Chlamydial infection: Screening 2001. In: Guide to Clinical Preventive Services, International Medical Publishing Co, Alexandria, VA 2001. p.332.
  24. American Academy of Pediatrics. Guidelines for Health Supervision, Third Ed, Stein M (Ed), American Academy of Pediatrics, Elk Grove, IL 1997.
  25. American College of Obstetricians and Gynecologists. Guidelines for Women's Health Care. American College of Obstetricians and Gynecologists, Washington, DC 1996.
  26. American Medical Association. AMA Guidelines for Adolescent Preventive Services (GAPS), Elster A, Kuznets N (Eds), Williams & Wilkins, Baltimore, MD 1994.
  27. Shafer MA, Tebb KP, Pantell RH, et al. Effect of a clinical practice improvement intervention on Chlamydial screening among adolescent girls. JAMA 2002; 288:2846.
  28. National Committee on Quality Assurance. State of managed care quality report. National Committee for Quality Assurance, Washington, DC 2001.
  29. Soper DE, Brockwell NJ, Dalton HP, Johnson D. Observations concerning the microbial etiology of acute salpingitis. Am J Obstet Gynecol 1994; 170:1008.
  30. Ness RB, Hillier SL, Kip KE, et al. Bacterial vaginosis and risk of pelvic inflammatory disease. Obstet Gynecol 2004; 104:761.
  31. Ness RB, Kip KE, Hillier SL, et al. A cluster analysis of bacterial vaginosis-associated microflora and pelvic inflammatory disease. Am J Epidemiol 2005; 162:585.
  32. Haggerty CL. Evidence for a role of Mycoplasma genitalium in pelvic inflammatory disease. Curr Opin Infect Dis 2008; 21:65.
  33. Oakeshott P, Aghaizu A, Hay P, et al. Is Mycoplasma genitalium in women the "New Chlamydia?" A community-based prospective cohort study. Clin Infect Dis 2010; 51:1160.
  34. Thompson SE 3rd, Hager WD, Wong KH, et al. The microbiology and therapy of acute pelvic inflammatory disease in hospitalized patients. Am J Obstet Gynecol 1980; 136:179.
  35. Chow AW, Malkasian KL, Marshall JR, Guze LB. The bacteriology of acute pelvic inflammatory disease. Am J Obstet Gynecol 1975; 122:876.
  36. Sweet RL, Draper DL, Hadley WK. Etiology of acute salpingitis: influence of episode number and duration of symptoms. Obstet Gynecol 1981; 58:62.
  37. Sweet RL, Mills J, Hadley KW, et al. Use of laparoscopy to determine the microbiologic etiology of acute salpingitis. Am J Obstet Gynecol 1979; 134:68.
  38. Stemmer W. Uber die ursachen von eileiterentzundungen. Gentral fur Gynnak 1941; 65:1062.
  39. Suss AL, Homel P, Hammerschlag M, Bromberg K. Risk factors for pelvic inflammatory disease in inner-city adolescents. Sex Transm Dis 2000; 27:289.
  40. Lee NC, Rubin GL, Grimes DA. Measures of sexual behavior and the risk of pelvic inflammatory disease. Obstet Gynecol 1991; 77:425.
  41. Flesh G, Weiner JM, Corlett RC Jr, et al. The intrauterine contraceptive device and acute salpingitis: a multifactor analysis. Am J Obstet Gynecol 1979; 135:402.
  42. Rein MF. Epidemiology of gonococcal infection. In: The Gonococcus, Roberts RB (Ed), Wiley and Sons, New York 1977. p.1.
  43. Westrom, L, Mardh PA. Epidemiology, etiology, and prognosis of acute salpingitis: A study of 1,457 laparoscopically verified cases. In: Nongonococcal Urethritis and Related Diseases, Hobson D, Holmes KK (Eds), Am Soc Microbiol, Washington DC 1977. p.84.
  44. Weström L. Incidence, prevalence, and trends of acute pelvic inflammatory disease and its consequences in industrialized countries. Am J Obstet Gynecol 1980; 138:880.
  45. Centers for Disease Control and Prevention, Workowski KA, Berman SM. Sexually transmitted diseases treatment guidelines, 2006. MMWR Recomm Rep 2006; 55:1.
  46. Biro FM, Rosenthal SL, Kiniyalocts M. Gonococcal and chlamydial genitourinary infections in symptomatic and asymptomatic adolescent women. Clin Pediatr (Phila) 1995; 34:419.
  47. Lan J, Melgers I, Meijer CJ, et al. Prevalence and serovar distribution of asymptomatic cervical Chlamydia trachomatis infections as determined by highly sensitive PCR. J Clin Microbiol 1995; 33:3194.
  48. Hillis SD, Nakashima A, Marchbanks PA, et al. Risk factors for recurrent Chlamydia trachomatis infections in women. Am J Obstet Gynecol 1994; 170:801.
  49. Weström L. Effect of acute pelvic inflammatory disease on fertility. Am J Obstet Gynecol 1975; 121:707.
  50. Ness RB, Soper DE, Holley RL, et al. Hormonal and barrier contraception and risk of upper genital tract disease in the PID Evaluation and Clinical Health (PEACH) study. Am J Obstet Gynecol 2001; 185:121.
  51. Eschenbach DA, Harnisch JP, Holmes KK. Pathogenesis of acute pelvic inflammatory disease: role of contraception and other risk factors. Am J Obstet Gynecol 1977; 128:838.
  52. Niruthisard S, Roddy RE, Chutivongse S. Use of nonoxynol-9 and reduction in rate of gonococcal and chlamydial cervical infections. Lancet 1992; 339:1371.
  53. Ness RB, Randall H, Richter HE, et al. Condom use and the risk of recurrent pelvic inflammatory disease, chronic pelvic pain, or infertility following an episode of pelvic inflammatory disease. Am J Public Health 2004; 94:1327.
  54. Gavin L, MacKay AP, Brown K, et al. Sexual and reproductive health of persons aged 10-24 years - United States, 2002-2007. MMWR Surveill Summ 2009; 58:1.
  55. Louv WC, Austin H, Perlman J, Alexander WJ. Oral contraceptive use and the risk of chlamydial and gonococcal infections. Am J Obstet Gynecol 1989; 160:396.
  56. Rubin GL, Ory HW, Layde PM. Oral contraceptives and pelvic inflammatory disease. Am J Obstet Gynecol 1982; 144:630.
  57. Ness RB, Keder LM, Soper DE, et al. Oral contraception and the recognition of endometritis. Am J Obstet Gynecol 1997; 176:580.
  58. Wølner-Hanssen P, Svensson L, Mårdh PA, Weström L. Laparoscopic findings and contraceptive use in women with signs and symptoms suggestive of acute salpingitis. Obstet Gynecol 1985; 66:233.
  59. Lee NC, Rubin GL, Borucki R. The intrauterine device and pelvic inflammatory disease revisited: new results from the Women's Health Study. Obstet Gynecol 1988; 72:1.
  60. Grimes DA. Intrauterine device and upper-genital-tract infection. Lancet 2000; 356:1013.
  61. Lee YC, Min D, Holcomb K, et al. Computed tomography guided core needle biopsy diagnosis of pelvic actinomycosis. Gynecol Oncol 2000; 79:318.
  62. Hall V, Talbot PR, Stubbs SL, Duerden BI. Identification of clinical isolates of actinomyces species by amplified 16S ribosomal DNA restriction analysis. J Clin Microbiol 2001; 39:3555.
  63. Lippes J. Pelvic actinomycosis: a review and preliminary look at prevalence. Am J Obstet Gynecol 1999; 180:265.
  64. Wølner-Hanssen P, Eschenbach DA, Paavonen J, et al. Association between vaginal douching and acute pelvic inflammatory disease. JAMA 1990; 263:1936.
  65. Rosenberg MJ, Phillips RS. Does douching promote ascending infection? J Reprod Med 1992; 37:930.